Advertisement

Evaluation of Protein Levels of the Receptor Tyrosine Kinase ErbB3 in Serum

  • Leandro S. D’Abronzo
  • Chong-Xian Pan
  • Paramita M. GhoshEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1655)

Abstract

The epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases (RTK) consists of four members: EGFR1/ErbB1/HER1, ErbB2/HER2, ErbB3/HER3, and HER4/ErbB4. Signaling through these receptors regulates many key cellular activities, such as cell division, migration, adhesion, differentiation, and apoptosis. The ErbB family has been shown to be overexpressed in different types of cancers and is a target of several inhibitors already in clinical trials. ErbB3 lacks a functional tyrosine kinase domain and therefore has not been as extensively studied as the other members of this family, but its importance in activating downstream pathways, such as the PI3K/Akt pathway, makes this RTK a worthy investigation target, especially in urothelial carcinoma where the PI3K/Akt pathway is vital for progression. In recent times, ErbB3 overexpression has been linked to drug resistance and progression of various diseases, especially cancer. ErbB3 levels in the serum were shown in many cases to be reflective of its role in disease progression, and therefore detection of serum ErbB3 levels during treatment may be of importance.

Here we describe two methods for detecting ErbB3 protein in serum from patients who have undergone a clinical trial, utilizing two well-established methods in molecular biology—western blotting and ELISA, focusing on sample preparation and troubleshooting.

Key words

EGFR ERBB3 Serum Urothelial carcinoma Western blot Elisa 

Notes

Acknowledgement

This work was supported by Biomedical Laboratory Research & Development (BLRD) Merit Awards (I01BX000400, PMG; I01BX001784, CXP) from the Department of Veterans Affairs, and by the National Institutes of Health (Awards R01CA133209 and R01CA185509, PMG).

References

  1. 1.
    Jones RB, Gordus A, Krall JA, MacBeath G (2006) A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 439(7073):168–174CrossRefPubMedGoogle Scholar
  2. 2.
    Gschwind A, Fischer OM, Ullrich A (2004) The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4(5):361–370CrossRefPubMedGoogle Scholar
  3. 3.
    Negro A, Brar BK, Lee KF (2004) Essential roles of Her2/erbB2 in cardiac development and function. Recent Prog Horm Res 59:1–12CrossRefPubMedGoogle Scholar
  4. 4.
    Corfas G, Roy K, Buxbaum JD (2004) Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia. Nat Neurosci 7(6):575–580CrossRefPubMedGoogle Scholar
  5. 5.
    Garratt AN, Ozcelik C, Birchmeier C (2003) ErbB2 pathways in heart and neural diseases. Trends Cardiovasc Med 13(2):80–86CrossRefPubMedGoogle Scholar
  6. 6.
    Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway KL III (1994) Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci U S A 91(17):8132–8136CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Carraway KL 3rd, Cantley LC (1994) A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell 78(1):5–8CrossRefPubMedGoogle Scholar
  8. 8.
    Hynes NE, MacDonald G (2009) ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21(2):177–184CrossRefPubMedGoogle Scholar
  9. 9.
    Arteaga CL, Engelman JA (2014) ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 25(3):282–303CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Baselga J, Swain SM (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9(7):463–475CrossRefPubMedGoogle Scholar
  11. 11.
    Amsellem-Ouazana D, Bièche I, Tozlu S, Botto H, Debré B, Lidereau R (2006) Gene expression profiling of ERBB receptors and ligands in human transitional cell carcinoma of the bladder. J Urol 175(3):1127–1132CrossRefPubMedGoogle Scholar
  12. 12.
    Brincks EL, Risk MC, Griffith TS (2013) PMN and anti-tumor immunity–the case of bladder cancer immunotherapy. Semin Cancer Biol 23(3):183–189CrossRefPubMedGoogle Scholar
  13. 13.
    Vishnu P, Mathew J, Tan WW (2011) Current therapeutic strategies for invasive and metastatic bladder cancer. Onco Targets Ther 4:97–113PubMedPubMedCentralGoogle Scholar
  14. 14.
    Winquist E, Kirchner TS, Segal R, Chin J, Lukka H (2004) Genitourinary cancer disease site group CCOPiE-bCPGI. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 171(2 Pt 1):561–569CrossRefPubMedGoogle Scholar
  15. 15.
    Zachos I, Konstantinopoulos PA, Tzortzis V et al (2010) Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise. Expert Opin Investig Drugs 19(7):875–887CrossRefPubMedGoogle Scholar
  16. 16.
    Chow NH, Liu HS, Yang HB, Chan SH, Su IJ (1997) Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma. An immunohistochemical study. Virchows Arch 430(6):461–466CrossRefPubMedGoogle Scholar
  17. 17.
    Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS (2001) Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 7(7):1957–1962PubMedGoogle Scholar
  18. 18.
    Dyrskjot L, Kruhoffer M, Thykjaer T et al (2004) Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 64(11):4040–4048CrossRefPubMedGoogle Scholar
  19. 19.
    Lee JS, Leem SH, Lee SY et al (2010) Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol 28(16):2660–2667CrossRefPubMedGoogle Scholar
  20. 20.
    Modlich O, Prisack HB, Pitschke G et al (2004) Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles. Clin Cancer Res 10(10):3410–3421CrossRefPubMedGoogle Scholar
  21. 21.
    Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C (2006) Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 24(5):778–789CrossRefPubMedGoogle Scholar
  22. 22.
    NCI (2013) The Cancer Genome Atlas - Bladder Urothelial Carcinoma DNA Copy Number Data In: Insititue TNc, ed. http://tcga-data.nci.nih.gov/tcga/: Oncomine
  23. 23.
    Mooso BA, Vinall RL, Mudryj M, Yap SA (2015) deVere white RW, Ghosh PM. The role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidence. J Urol 193(1):19–29CrossRefPubMedGoogle Scholar
  24. 24.
    Wulfing C, Machiels JP, Richel DJ et al (2009) A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 115(13):2881–2890CrossRefPubMedGoogle Scholar
  25. 25.
    Sithanandam G, Anderson LM (2008) The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther 15(7):413–448CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Jathal MK, Chen L, Mudryj M, Ghosh PM (2011) Targeting ErbB3: the new RTK(id) on the prostate cancer block. Immunol Endocr Metab Agents Med Chem 11(2):131–149CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Lee H, Akita RW, Sliwkowski MX, Maihle NJ (2001) A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4. Cancer Res 61(11):4467–4473PubMedGoogle Scholar
  28. 28.
    Lin SH, Lee YC, Choueiri MB et al (2008) Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin Cancer Res 14(12):3729–3736CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Chen N, Ye XC, Chu K et al (2007) A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res 67(14):6544–6548CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Lin SH, Cheng CJ, Lee YC et al (2008) A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene 27(39):5195–5203CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Bei R, Masuelli L, Moriconi E et al (1999) Immune responses to all ErbB family receptors detectable in serum of cancer patients. Oncogene 18(6):1267–1275CrossRefPubMedGoogle Scholar
  32. 32.
    Morrison MM, Williams MM, Vaught DB et al (2016) Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth. Oncogene 35(9):1143–1152CrossRefPubMedGoogle Scholar
  33. 33.
    Ghasemi R, Rapposelli IG, Capone E et al (2014) Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer. Oncogene 3:e117CrossRefGoogle Scholar
  34. 34.
    Zhu S, Belkhiri A, El-Rifai W (2011) DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib. Gastroenterology 141(5):1738–48 e1–2CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Liu W, Barnette AR, Andreansky S, Landgraf R (2016) ERBB2 overexpression establishes ERBB3-dependent hypersensitivity of breast cancer cells to Withaferin A. Mol Cancer Ther 15(11):2750–2757CrossRefPubMedGoogle Scholar
  36. 36.
    Chen JY, Chen YJ, Yen CJ, Chen WS, Huang WC (2016) HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3. Oncotarget 7(1):473–489PubMedGoogle Scholar
  37. 37.
    Butler JE (2000) Enzyme-linked immunosorbent assay. J Immunoass 21(2–3):165–209CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2018

Authors and Affiliations

  • Leandro S. D’Abronzo
    • 1
    • 2
  • Chong-Xian Pan
    • 1
    • 2
    • 3
  • Paramita M. Ghosh
    • 1
    • 2
    • 4
    • 5
    Email author
  1. 1.VA Northern California Health Care SystemUniversity of California at DavisSacramentoUSA
  2. 2.Department of UrologyUniversity of California at DavisSacramentoUSA
  3. 3.Division of Hematology and Oncology, Department of Internal MedicineUniversity of California at DavisSacramentoUSA
  4. 4.Department of Biochemistry and Molecular MedicineUniversity of California at DavisSacramentoUSA
  5. 5.Department of UrologyUniversity of California Davis School of MedicineSacramentoUSA

Personalised recommendations